Trial NCT05057169
Publication Leung N, medRxiv, 2022
Primary outcome on the report: Immunogenicity at 28 days after the third dose of either BNT162b2 or CoronaVac, measured as geometric mean titer (GMT) of SARS-CoV-2 serum neutralising antibodies using plaque reduction neutralization test (PRNT50)

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.